jcp conference-coverage

Conference Coverage

Care Team Burden Impact on Treatment Selection for CLL and Lymphoid Malignancies

12/07/2021

Study findings suggest domain-specific appraisal of electronic communication portals can improve health care delivery and intervention and maximize patient-centered care while decreasing therapy-related health care team burden.

Study findings suggest...

12/07/2021

Journal of Clinical Pathways

Conference Coverage

Budget Impact of Blood-Based Biomarker Assay in Patients With Metastatic Breast Cancer

12/07/2021

Janelle Bradley ;

Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...

Use of a blood-based biomarker...

12/07/2021

Journal of Clinical Pathways

Conference Coverage

Biomarker Testing and Alpelisib Treatment Patterns for Metastatic Breast Cancer in the Community Oncology Setting

12/07/2021

Janelle Bradley ;

A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.

A study presented at the 2021...

12/07/2021

Journal of Clinical Pathways

Conference Coverage

Oncologists’ Perspectives on Patient-centered Dosing for Metastatic Breast Cancer

12/06/2021

Janelle Bradley ;

Medical oncologists reported that a high percentage of patients experience distressing toxicity, a need for acute care, and dose interruptions with standard delivery of therapy for metastatic breast cancer.

Medical oncologists reported...

12/06/2021

Journal of Clinical Pathways

Conference Coverage

Third-Line Chemotherapy With or Without Trastuzumab-Based Therapy for Metastatic Breast Cancer

12/06/2021

Janelle Bradley ;

The inclusion of trastuzumab-based therapy with chemotherapy was associated with improved survival outcomes compared with chemotherapy alone for the third-line treatment of metastatic breast cancer.

The inclusion of...

12/06/2021

Journal of Clinical Pathways

Conference Coverage

Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases

12/06/2021

Janelle Bradley ;

Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.

Palbociclib plus letrozole is...

12/06/2021

Journal of Clinical Pathways

Conference Coverage

Treatment Preferences for Relapsed/Refractory MM in Later Lines of Therapy

10/07/2021

Marta Rybczynski ;

Findings from a recent study revealed that oncologists place higher relative importance on OS, PFS, and ORR, and prefer a decreased risk of grade 3/4 keratopathy and thrombocytopenia when choosing later line therapies in relapsed/refractory...

Findings from a recent study...

10/07/2021

Journal of Clinical Pathways

Conference Coverage

HRQOL With Nivolumab Plus Chemo vs Chemo Alone Among Patients With Gastrointestinal Cancers

10/04/2021

Marta Rybczynski ;

Compared with chemotherapy alone, nivolumab added to chemotherapy maintained health-related quality of life with a decreased risk of symptom deterioration in patients with previously untreated advanced or metastatic gastric...

Compared with chemotherapy...

10/04/2021

Journal of Clinical Pathways

Conference Coverage

Trends in Total and Out-of-Pocket Cost Among Privately Insured Patients With Cancer

10/04/2021

Marta Rybczynski ;

The rise in cancer treatment costs in combination with the increase of cost-sharing have financially burdened privately insured, nonelderly patients with cancer.

The rise in cancer treatment...

10/04/2021

Journal of Clinical Pathways

Conference Coverage

10/04/2021

Marta Rybczynski ;

According to a study presented at the 2021 ASCO Quality Care Symposium, cost-related prescription nonadherence is associated with higher health care cost responsibility in cancer survivors, especially for those living in rural compared to...

According to a study presented...

10/04/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products